Article

OHTS changing way ocular hypertension is treated

Baltimore-Treatment of people with ocular hypertension without a diagnosis of glau-coma has been poorly understood, but there is no doubt that the Ocular Hypertension Treatment Study (OHTS) has brought the field a lot farther.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
Related Content
(Image credit: AdobeStock/iQoncept)
March 26th 2025

Beyond mentoring: The power of sponsorship and advocacy in ophthalmology

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Character Biosciences secures $93 million series B financing round
March 26th 2025

Character Biosciences secures $93 million series B financing round

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Alcon agrees to purchase LENSAR
March 25th 2025

Alcon agrees to purchase LENSAR

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint
March 24th 2025

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

© 2025 MJH Life Sciences

All rights reserved.